Glimcity-M2 Tablet SR is a combination oral hypoglycemic agent containing Glimepiride 2 mg and Metformin 500 mg, formulated for sustained release to provide effective glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving peripheral insulin sensitivity, and enhancing glucose uptake by tissues. The sustained-release formulation ensures gradual drug release, minimizing gastrointestinal side effects commonly associated with immediate-release metformin and improving patient compliance. Glimcity-M2 is indicated as an adjunct to diet and exercise for the management of type 2 diabetes when monotherapy with either agent is insufficient. It is particularly beneficial for patients with insulin resistance and inadequate glycemic control. Dosage should be individualized based on patient response and tolerability, with regular monitoring of blood glucose levels and renal function. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoxia. This combination therapy offers a complementary mechanism of action, optimizing glycemic control while minimizing adverse effects, thus improving overall diabetes management outcomes.